Longeveron Dirección

Dirección controles de criterios 0/4

El CEO de Longeveron es Mohamed Wa'el Hashad , nombrado en Feb 2023, tiene una permanencia de 1.75 años. compensación anual total es $1.66M, compuesta por 25.9% salario y 74.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.94% de las acciones de la empresa, por valor de $520.35K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 2.4 años, respectivamente.

Información clave

Mohamed Wa'el Hashad

Chief Executive Officer (CEO)

US$1.7m

Compensación total

Porcentaje del salario del CEO	25.9%
Permanencia del CEO	1.8yrs
Participación del CEO	1.9%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	2.4yrs

Actualizaciones recientes de la dirección

Recent updates

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Jul 07

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mohamed Wa'el Hashad en comparación con los beneficios de Longeveron?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$2m	US$431k	-US$22m

Compensación vs. Mercado: La compensación total de Mohamed Wa'el($USD1.66M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD650.80K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Mohamed Wa'el con los resultados de la empresa.

CEO

Mohamed Wa'el Hashad (62 yo)

1.8yrs

Permanencia

US$1,662,854

Compensación

Mr. Mohamed Wa'el Ahmed Hashad, M.B.A. has been Chief Executive Officer at Longeveron Inc. since February 2023 and also has been its Director since June 09, 2023. Mr. Hashad has been Independent Director a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Joshua Hare	Co-Founder	10.8yrs	US$87.13k	8.29% $ 2.2m
Mohamed Wa'el Hashad	CEO & Director	1.8yrs	US$1.66m	1.94% $ 520.3k
Lisa Locklear	CFO & Treasurer	1.3yrs	US$604.67k	1.1% $ 296.0k
Paul Lehr	International Executive Director	no data	US$554.06k	1.11% $ 298.4k
Dan Gincel	Senior Vice President of Strategic Collaborations & Scientific Affairs	3.5yrs	sin datos	sin datos
Nataliya Agafonova	Chief Medical Officer	1.3yrs	sin datos	1.1% $ 295.1k
Lisa McClain-Moss	Vice President of Manufacturing	no data	sin datos	sin datos
Brian Rash	VP of Research & Discovery	no data	sin datos	sin datos
Elly Ryu	VP & Corporate Controller	less than a year	sin datos	sin datos
Michael Mannarino	VP & Corporate Controller	less than a year	sin datos	sin datos

1.3yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LGVN no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Joshua Hare	Co-Founder	10.8yrs	US$87.13k	8.29% $ 2.2m
Mohamed Wa'el Hashad	CEO & Director	1.4yrs	US$1.66m	1.94% $ 520.3k
Roger Hajjar	Independent Director	less than a year	sin datos	sin datos
Richard Kender	Independent Director	less than a year	sin datos	sin datos
Joe G. Garcia	Member of Scientific Advisory Board	no data	sin datos	sin datos
Khoso Baluch	Independent Director	1.4yrs	US$47.78k	0.10% $ 27.8k
Jeremy Walston	Member of Scientific Advisory Board	no data	sin datos	sin datos
Elena Volpi	Member of Scientific Advisory Board	no data	sin datos	sin datos
Hidenori Arai	Member of Scientific Advisory Board	no data	sin datos	sin datos
Neil Hare	Director	9.2yrs	US$52.13k	2.13% $ 570.8k
Rock Soffer	Director	4.7yrs	US$55.63k	1.45% $ 390.0k
Ursula Ungaro	Independent Director	3.4yrs	US$62.63k	0.0035% $ 934.5

2.4yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de LGVN no se considera experimentada (2.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Longeveron Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Longeveron Inc. Appoints Devin Blass as Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, Effective December 2, 2024

Longeveron Inc. Elects Neha Motwani to Its Board of Directors

Longeveron Inc. Appoints Roger Hajjar to Board of Directors

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Recent updates

Consensus EPS estimates fall by 19%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Longeveron Inc. Appoints Devin Blass as Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, Effective December 2, 2024

Longeveron Inc. to Report Q3, 2024 Results on Nov 12, 2024

Longeveron Inc. Presents Lomecel-B™? Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron Inc. Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS)

Consensus estimates of losses per share improve by 12%

Price target decreased by 31% to US$8.32

Consensus revenue estimates fall by 14%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Longeveron Inc. to Report Q2, 2024 Results on Aug 14, 2024

Consensus revenue estimates increase by 21%

Price target decreased by 10% to US$11.32

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

Consensus EPS estimates upgraded to US$3.42 loss

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $9.000005 million.

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

Longeveron Inc. Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Longeveron Inc. Elects Neha Motwani to Its Board of Directors

Longeveron Inc. Appoints Roger Hajjar to Board of Directors

Price target decreased by 12% to US$12.30

Consensus EPS estimates upgraded to US$3.91 loss

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Consensus revenue estimates increase by 931%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Longeveron Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus EPS estimates upgraded to US$5.85 loss

Price target decreased by 48% to US$37.50

New major risk - Share price stability

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $5.248428 million.

New major risk - Shareholder dilution

New major risk - Market cap size

Longeveron Announces 1-For-10 Reverse Stock Split to Regain Compliance

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Full year 2023 earnings: EPS misses analyst expectations

Longeveron Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $2.365 million.

Longeveron Inc. has filed a Follow-on Equity Offering in the amount of $2.195588 million.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’S Disease

Long-Term Survival Data from Longeveron’s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association

Longeveron Inc. to Report Q3, 2023 Results on Nov 10, 2023

Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B™? for the Treatment of Mild Alzheimer's

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%

Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer’s Disease

Director exercised options to buy US$70k worth of stock.

New major risk - Revenue size

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q2, 2023 Results on Aug 11, 2023

Longeveron Inc. Announces the Appointment of Lisa Locklear as Chief Financial Officer, Effective July 31, 2023

Longeveron Inc. Appoints Nataliya Agafonova M.D. as Chief Medical Officer

High number of new directors

Longeveron Inc. Approves Bord Appointments

Longeveron Inc. Announces Resignation of James Clavijo as CFO

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.90 loss per share (vs US$0.90 loss in FY 2021)

Price target decreased to US$15.50

Longeveron Provides Corporate Update

Consensus forecasts updated

Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind